Last reviewed · How we verify
Oral Viscous Budesonide
Oral viscous budesonide is a corticosteroid that reduces inflammation in the esophagus and gastrointestinal tract by suppressing local immune responses.
Oral viscous budesonide is a corticosteroid that reduces inflammation in the esophagus and gastrointestinal tract by suppressing local immune responses. Used for Eosinophilic esophagitis.
At a glance
| Generic name | Oral Viscous Budesonide |
|---|---|
| Also known as | Pulmicort |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Corticosteroid (topical/inhaled formulation) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | FDA-approved |
Mechanism of action
Budesonide is a glucocorticoid receptor agonist that binds to intracellular glucocorticoid receptors, leading to suppression of inflammatory gene transcription and reduced production of pro-inflammatory cytokines. The viscous oral formulation allows the drug to coat and remain in contact with affected mucosal surfaces in the esophagus and upper GI tract, providing topical anti-inflammatory effects with minimal systemic absorption.
Approved indications
- Eosinophilic esophagitis
Common side effects
- Candidiasis (oral/esophageal)
- Headache
- Nausea
- Abdominal pain
Key clinical trials
- Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis (PHASE2)
- Eosinophilic Esophagitis Clinical Therapy Comparison Trial (PHASE2)
- Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis (PHASE4)
- Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis (PHASE2)
- Oral Viscous Budesonide in Anastomotic Stricture After Esophageal Atresia Repair (OVB in EA) (NA)
- Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis (PHASE4)
- The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Viscous Budesonide CI brief — competitive landscape report
- Oral Viscous Budesonide updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI